Distinct Effects of Unfractionated Heparin versus Bivalirudin on Circulating Angiogenic Peptides
Distinct Effects of Unfractionated Heparin versus Bivalirudin on Circulating Angiogenic Peptides
复制标题
DOI：
10.1371/journal.pone.0034344
复制
发表时间：
2012-04-11
期刊：
影响因子：
3.7
通讯作者：
Jaffe, Iris Z.
中科院分区：
文献类型：
--
作者：
Kapur, Navin K.;Shenoy, Chetan;Jaffe, Iris Z.
背景：治疗性血管生成、干细胞和祖细胞治疗的人类研究未能证明一致的临床益处。最近的研究表明，肝素可以增加血液中抗血管生成肽的水平。鉴于肝素在经皮和外科手术中的广泛应用，包括作为治疗性血管生成和细胞治疗益处研究的一部分，我们比较了未分离肝素（UFH）对血管生成肽的作用与比伐鲁定的作用，比伐鲁定是一种相对较新的抗凝剂，其对血管生成肽的作用尚未被研究。方法/主要发现：我们通过酶联免疫吸附试验（ELISA）测量了16例选择性经皮冠状动脉介入治疗患者的可溶性纤维样酪氨酸激酶-1 （sFLT1）、胎盘生长因子（PlGF）、血管内皮生长因子（VEGF）和可溶性内酰胺（sEng）血清水平。与基线值相比，在UFH治疗30分钟内，sFLT1和PlGF水平分别增加了2629 +/- 313%和253 +/- 54% （p500%）
Background: Human studies of therapeutic angiogenesis, stem-cell, and progenitor-cell therapy have failed to demonstrate consistent clinical benefit. Recent studies have shown that heparin increases circulating levels of anti-angiogenic peptides. Given the widely prevalent use of heparin in percutaneous and surgical procedures including those performed as part of studies examining the benefit of therapeutic angiogenesis and cell-based therapy, we compared the effects of unfractionated heparin (UFH) on angiogenic peptides with those of bivalirudin, a relatively newer anticoagulant whose effects on angiogenic peptides have not been studied.Methodology/Principal Findings: We measured soluble fms-like tyrosine kinase-1 (sFLT1), placental growth factor (PlGF), vascular endothelial growth factor (VEGF), and soluble Endoglin (sEng) serum levels by enzyme linked immunosorbent assays (ELISA) in 16 patients undergoing elective percutaneous coronary intervention. Compared to baseline values, sFLT1 and PlGF levels increased by 2629 +/- 313% and 253 +/- 54%, respectively, within 30 minutes of UFH therapy (p500% (p